In autologous hematopoietic stem cell transplantation, another MS treatment modality, NK cells reconstitute faster than CD4+ T cells and regulate disease-promoting Th17 cells via NKG2D-mediated cytotoxicity, preventing lesion formation and relapse (32). This evidence concerns the gene KLRK1 and myeloid sarcoma.